Version May 2024
Common cold: Note: For best results, begin therapy 24 to 48 hours prior to symptom onset: Oral: Dissolve one 13.3 mg lozenge in mouth every 2 to 4 hours as needed. Maximum: 6 lozenges daily.
Dietary supplement: Oral: One capsule/tablet daily or as directed by health care provider.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
(For additional information see "Zinc gluconate: Pediatric drug information")
Common cold: Note: Consult product-specific labeling for manufacturer-recommended ages. For best results, begin therapy 24 to 48 hours prior to symptom onset: Cold-Eeze Lozenge: Children ≥12 years and Adolescents: Oral topical: Dissolve one lozenge in mouth every 2 to 4 hours as needed. Age-dependent maximum daily dose: 12 to 17 years: 4 lozenges/day; ≥18 years: 6 lozenges/day.
Zinc deficiency, treatment: Limited data available: Note: Dosage expressed in terms of elemental zinc (Kliegman 2016)
Acquired: Infants, Children, and Adolescents: Oral: 0.5 to 1 mg/kg/day
Acrodermatitis enteropathica: Infants, Children, and Adolescents: Oral: 3 mg/kg/day
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined; may vary with different salts. Adverse reactions reported with excess dietary zinc (IOM 2001).
Central nervous system: Headache
Endocrine & metabolic: Copper deficiency, decreased HDL cholesterol, decreased LDL cholesterol
Gastrointestinal: Abdominal cramps, decreased appetite, diarrhea, epigastric pain, gastrointestinal distress, nausea, vomiting
Hematologic & oncologic: Immunodeficiency
There are no contraindications listed in the manufacturer's labeling.
Disease related concerns:
• Malabsorption syndromes: Absorption of zinc may be decreased and urinary excretion increased in patients with Crohn’s disease, short bowel syndrome and sprue (IOM 2001).
Other warnings/precautions:
• Self-medication (OTC use): When used for self medication (OTC) to treat the common cold, notify health care provider if symptoms continue for greater than 7 days. Increase fluid intake during therapy.
Strengths of zinc gluconate products in the Dosage Forms field are expressed as elemental zinc. Other commercially available products may be expressed as zinc gluconate salt; zinc gluconate salt contains approximately 14.3% elemental zinc.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Capsule, Oral [preservative free]:
Zn-50: 50 mg [dye free, sugar free, yeast free]
Lozenge, Mouth/Throat:
Cold-Eeze: 13.3 mg (2 ea, 10 ea, 18 ea, 24 ea) [gluten free; cherry flavor]
Cold-Eeze: 13.3 mg (18 ea, 24 ea) [gluten free; honey-lemon flavor]
Cold-Eeze: 13.3 mg (18 ea) [gluten free; tropical orange flavor]
Generic: 10 mg (100 ea)
Lozenge, Mouth/Throat [preservative free]:
Cold-Eeze Sugar Free: 13.3 mg (18 ea) [gluten free, no artificial color(s), sugar free]
Cold-Eeze Sugar Free: 13.3 mg (18 ea, 24 ea) [gluten free, no artificial color(s), sugar free; cherry flavor]
Tablet, Oral:
Generic: 15 mg, 30 mg, 50 mg, 100 mg
Tablet, Oral [preservative free]:
Generic: 50 mg [DSC]
Yes
Tablets (Zinc Gluconate Oral)
50 mg (per each): $0.05
100 mg (per each): $0.07
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: Administer with food to avoid stomach upset.
Lozenge: Dissolve in mouth; do not chew. Avoid eating or drinking for 15 minutes after administration.
Oral: May be taken with food to avoid stomach upset.
Lozenge: Dissolve in mouth; do not chew.
Common cold: To reduce the duration and severity of symptoms associated with the common cold.
Dietary supplement: For use as a dietary supplement.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Risk X: Avoid combination
Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Risk D: Consider therapy modification
Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider therapy modification
Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir. Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir. Risk D: Consider therapy modification
Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Risk D: Consider therapy modification
Dolutegravir: Zinc Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral zinc salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral zinc salts. Risk D: Consider therapy modification
Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Risk D: Consider therapy modification
Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Risk D: Consider therapy modification
Levonadifloxacin: Zinc Salts may decrease the serum concentration of Levonadifloxacin. Risk X: Avoid combination
PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Risk D: Consider therapy modification
Quinolones: Zinc Salts may decrease the serum concentration of Quinolones. Management: Give oral quinolones at several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts. Risk D: Consider therapy modification
Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Risk D: Consider therapy modification
Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat. Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products. Risk D: Consider therapy modification
Tetracyclines: Zinc Salts may decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. Management: Separate administration of oral tetracycline derivatives and oral zinc salts by at least 2 hours to minimize this interaction. Risk D: Consider therapy modification
Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation. Risk D: Consider therapy modification
Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products. Risk X: Avoid combination
Ethanol: Long term consumption decreases zinc absorption and increases urinary excretion; daily zinc requirements may be increased (IOM 2001).
Zinc crosses the placenta and can be measured in the cord blood and placenta. Fetal concentrations are regulated by the placenta (de Moraes 2011). The RDA is increased during pregnancy (IOM 2001).
Zinc is found in breast milk; concentrations decrease over the first 6 months of lactation. Concentrations are generally not affected by dietary supplementation. The maternal RDA is increased in nursing women (IOM 2001).
Dietary sources of zinc are red meat, some seafood, and whole grains. When dietary phytate is increased (as with some vegetarian diets), dietary absorption of zinc is decreased (IOM 2001).
Lozenge: Avoid citrus fruits/juices and products containing citric acid within 30 minutes prior to or after use.
Dietary adequate intake (AI) (IOM 2001): Dose expressed as elemental zinc
1 to 6 months: 2 mg daily
Dietary recommended daily allowance (RDA) (IOM 2001): Dose expressed as elemental zinc
7 to 12 months: 3 mg daily
1 to 3 years: 3 mg daily
4 to 8 years: 5 mg daily
9 to 13 years: 8 mg daily
14 to 18 years: Females: 9 mg daily; Males: 11 mg daily; Pregnancy: 12 mg daily; Lactation: 13 mg daily
>18 years: Females: 8 mg daily; Males: 11 mg daily; Pregnancy: 11 mg daily: Lactation: 12 mg daily
Zinc, serum: 75 to 140 mcg/dL (11.5 to 21.4 mmol/L) (ABIM 2023). Note: Serum zinc concentrations are dependent on age and sex, and may fluctuate depending on time of blood draw, infection, hormone changes, and muscle catabolism; correlation with clinical signs and/or symptoms of zinc deficiency is recommended (NIH 2022).
Zinc is an essential mineral that is found in almost every cell. It stimulates the activity of approximately 100 enzymes (IOM 2001). Zinc deficiency may be associated with an increased risk of infection. When used to treat the common cold, zinc may interfere with rhinovirus cleavage or adhesion, and may protect plasma membranes from microbial toxins and complement (Nahas 2011).
Absorption: Small intestine (IOM 2001).
Distribution: Stored primarily in skeletal muscle and bone (IOM 2001).
Protein binding: Albumin and alpha 1-macroglobulin (Foote 1984).
Excretion: Feces and urine (IOM 2001).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
